Hamilton Thorne, Ltd.
Dr. Kate Torchilin joined Hamilton Thorne as its Chief Executive Officer, President, and as a Director in January 2024. Previously, Kate was the President of the Biologicals and Chemicals Division at Thermo Fisher Scientific, where she was responsible for the development, manufacture, and global commercialization of their cell culture, cell therapy and chemical business. Kate also has over 20 years of experience in the life sciences and healthcare industries, including, serving as Global Head of Connected Health and Women’s Health at Alere, Inc., where she was responsible for their global business in diagnostic testing supporting healthy pregnancy. Kate earned a PhD. in Biochemistry from Tufts University and an MBA from Harvard Business School.
Mr. Fragasso joined Hamilton Thorne in September 2022. Most recently, he served as CFO of Fluence Corporation (ASX:FLC), a provider of water and wastewater treatment solutions where he was responsible for all aspects of the Company’s global financial operations, reporting, accounting, treasury, administration, planning, and internal controls. Before joining Fluence, he served as CFO for Desalitech, prior to its acquisition by DuPont. He has also served as CFO and VP of Operations for Nuvera Fuel Cells, Inc. (part of Hess Corporation Group) and spent six years in public accounting and corporate finance with Deloitte.
Justin Jaundoo joined Hamilton Thorne in 2021. As a senior leader with significant experience in strategic initiatives and implementation, full-cycle M&A execution, and operational excellence. Justin has held various strategy, corporate development, and operational roles throughout his career. Before joining Hamilton Thorne, Justin was a Director of Strategy and Corporate Development at Interactions where he was responsible for identifying, developing and executing acquisitions, strategic partnerships, and joint ventures. Prior to that he led strategy and corporate development for GCP, and held operational, strategic and financial roles at Nortek, ipCapital, and GE.
Brett Fulton joined Hamilton Thorne in May 2021. Brett has extensive global medical device experience having worked for both large and small global companies, such as Stryker, Abbott and Microline Surgical. Brett has successfully built and managed productive local and global teams focused on driving both top and bottom-line growth through direct and third party distributor sales.
Education: University of Cape Town
Julia joined the Gynemed team in 2015 as a leader in regulatory affairs. Further she played an important role in the quality management department as well as the research and development team before assuming the Managing Director position in 2020. Julia previously worked as a research scientist in the field of reproductive medicine. After acquiring her PhD in Hanover, Germany, in 2008, she was in charge of an IVF lab at a German research facility where she focused on the influence of culture media on embryo development and epigenetics.
Joel joined Embryotech as its Vice President of Sales and Marketing in March 2018 and was promoted to Senior Vice President and General Manager. Joel has over 17 years of experience in the ART field, serving in a variety of sales, marketing and product management roles at Hamilton Thorne and Eppendorf North America.
Adrian joined Planer in 2014 as its Sales & Marketing Manager before becoming Managing Director in 2018. For the majority of his working career Adrian has held various sales, marketing, and technical support roles within large Life Science corporations, lately Terumo (injection & infusion products) and Phillips Medical Systems (imaging systems).
Kamilla joined IVFtech in 2010 as COO. Her primary task and priorities have been improving and optimizing all operation procedures to ensure daily performance, and ensuring that IVFtech can keep delivering the customized solutions they are known for. Before becoming Managing Director in 2021 Kamilla also played a key role in the quality management department.